文献速递胸部肿瘤头颈与中枢神经肿瘤

循环肿瘤DNA分析用于孤立性中枢神经系统进展的癌基因依赖非小细胞肺癌

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression.
PubMed 文献 · J Thorac Oncol · 2019-12-13

本研究纳入247例晚期NSCLC患者,按进展模式分为孤立性中枢神经系统进展(iCNS)、仅颅外进展(noCNS)和两者兼有(cCNS),分析血浆ctDNA。iCNS组ctDNA阳性率为52%,显著低于noCNS组的84%和cCNS组的92%(p<0.00001),驱动基因和耐药基因改变检出率也较低。iCNS且ctDNA阳性患者颅外进展风险更高(32% vs 7%,p=0.026)。

要点

  • iCNS患者血浆ctDNA阳性率仅52%,显著低于颅外进展患者。
  • iCNS患者驱动基因和耐药基因改变的ctDNA检出率均较低。
  • iCNS且ctDNA阳性者颅外进展风险更高,脑脊液cfDNA可作补充检测。

核心结论

  • 基于标记扩增子的二代测序在颅外病变NSCLC患者血浆ctDNA中基因改变检出率高,但在iCNS患者中检出率较低(52%)。
  • 脑脊液游离DNA等补充检测可能有用,需进一步证据理解iCNS患者的基因组 landscape。

研究设计与样本

  • 回顾性分析,筛选517例,纳入247例晚期NSCLC且基线组织已知基因组改变的患者。
  • 按进展模式分组:iCNS 54例,noCNS 99例,cCNS 94例;分别对应64、128、110份ctDNA样本。
  • 血浆ctDNA采用InVisionFirst-Lung二代测序,至少检出1个基因组改变定义为阳性;有脑脊液时分析脑脊液cfDNA。

主要发现

  • ctDNA阳性率:iCNS 52%,noCNS 84%,cCNS 92%(p < 0.00001)。
  • 驱动基因改变检出率:iCNS 37%,noCNS 77%,cCNS 73%。
  • 耐药基因改变检出率:iCNS 6%,noCNS 45%,cCNS 44%。
  • iCNS且ctDNA阳性患者颅外进展风险更高:32% vs 7%(p = 0.026)。
  • 12例iCNS患者中,血浆ctDNA阳性6例(50%),配对脑脊液阳性10例(83%)(p = 0.193)。

临床怎么用

  • 对iCNS患者,血浆ctDNA阴性不能排除基因组改变,可考虑脑脊液cfDNA补充检测。
  • iCNS且ctDNA阳性提示颅外进展风险较高,需加强颅外病灶监测。

局限性

  • 样本量有限,尤其iCNS组仅54例,脑脊液配对分析仅12例。
  • 脑脊液与血浆ctDNA阳性率差异未达统计学显著(p = 0.193)。
  • 需进一步证据理解iCNS患者的基因组 landscape。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In patients with oncogene-addicted NSCLC and isolated central nervous system progression (iCNS), tissue biopsy is challenging, and the clinical utility of plasma liquid biopsy (i.e., circulating tumor DNA [ctDNA]) is unknown. METHODS: Patients with advanced NSCLC with known baseline genomic alteration (GA) (EGFR, ALK, BRAF, KRAS, HER2, ROS1, MET, PIK3CA, STK11, TP53) on tissue were divided into three groups on the basis of their disease progression pattern: iCNS, extra-CNS only (noCNS), or both (cCNS). All patients with available plasma ctDNA were included and were analyzed by next-generation sequencing InVisionFirst-Lung. ctDNA was considered positive if at least one GA was detected. Cell-free tumor DNA was analyzed in cerebrospinal fluid when available. RESULTS: Out of 517 patients screened, 247 were included: 54 had iCNS, 99 had noCNS, and 94 had cCNS progressive disease (64, 128, and 110 ctDNA samples, respectively). CtDNA was positive in 52% iCNS versus 84% in noCNS and 92% in cCNS (p < 0.00001), with lower detection of driver (37% versus 77% and 73%, respectively) and resistance alterations (6% versus 45% and 44%). Patients with iCNS and positive ctDNA were more at risk of extra-CNS progression (32% versus 7%, p = 0.026). In 12 patients with iCNS, ctDNA was positive in six (50%) plasma and in 10 (83%) paired cerebrospinal fluid (p = 0.193). CONCLUSIONS: Although tagged amplicon-based next-generation sequencing has high detection rates of GA in plasma ctDNA in patients with NSCLC with extra-CNS disease, detection rate of GAs (52%) is lower in the subset of patients with iCNS disease. Complementary tests such as cerebrospinal fluid cell-free DNA may be useful. Further evidence would be beneficial to understand the genomic landscape in patients with NSCLC and iCNS.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Aldea M, Hendriks L, Mezquita L, et al. Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. J Thorac Oncol. 2019. PMID: 31843682. doi:10.1016/j.jtho.2019.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。